SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as investors weigh strong AI-driven fundamental growth projections against a broader cooling in the semiconductor sector. The community remains sharply divided, with many bulls viewing recent dips as a healthy buying opportunity supported by strong memory demand, while skeptical traders warn that recent parabolic gains have left the stock vulnerable to profit-taking and macro-economic pressures.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is attracting significant attention as community members discuss a potential take-private bid by Nelson Peltz's Trian Fund Management, which has fueled speculation of a major short squeeze given the stock's high short interest. Investors are actively debating the viability of a buyout, comparing the current valuation against growth initiatives like international expansion, while many look for a substantial price floor to shake out the bearish sentiment.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is experiencing heightened market activity following a strong quarterly earnings beat, fueling investor optimism regarding its transition from research to commercial hardware. While some members of the community express skepticism over its current revenue and valuation, bulls are actively focused on the company's strategic acquisitions and potential for a short squeeze amidst significant institutional interest.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is experiencing intense volatility and social media debate driven by recent dilution concerns and regulatory questions surrounding its indirect Anthropic holdings. Despite this, many in the community remain focused on the fund's heavy pre-IPO exposure to high-profile assets like SpaceX, viewing the current price action as an accumulation opportunity ahead of anticipated liquidity events.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to strong earnings and raised EBITDA guidance, while the market closely monitors the ongoing volatility in global LNG supply chains and Middle East geopolitical developments. The community remains focused on the company's aggressive growth, the impact of continued export terminal expansions, and the potential for a significant rerating as it outmaneuvers competitors.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility as traders weigh explosive momentum against concerns that leveraged decay and historical overbought conditions are setting the stage for a major market reversal. The community remains deeply polarized, with bulls leaning into aggressive AI-driven growth narratives while bears argue that massive retail participation and record-setting RSI levels signal an imminent and structural collapse.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF ($DRAM) is surging as institutional investors pile into the sector to gain concentrated exposure to a structural memory chip supercycle driven by massive AI infrastructure demand. Community sentiment remains intensely bullish, with many traders viewing the current volatility and dip-buying opportunities as a key strategy to capitalize on the persistent supply crunch for high-speed memory.

Token Cat Ltd. operates as a holding company, which engages in the operation of an omni-channel automotive marketplace. It offers auto shows, group-purchase facilitation, and virtual dealership services. The company was founded by Wei Wen and Jian Chen Sun in 2010 and is headquartered in Beijing, China.

Token Cat Ltd. - ADR

TuanChe Ltd - ADR

TuanChe is seeing significant investor attention driven by its low float and a strategic pivot toward cryptocurrency asset management, including the appointment of a new COO to lead these operations. Community members are actively comparing the stock's tight structure to recent high-momentum Chinese small-cap runners, frequently citing it as a potential breakout candidate due to its thin trading dynamics and recent strategic partnerships.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending as investors react to promising preclinical data showing 100% tumor clearance in ovarian cancer models, fueling high volume and intense community speculation about potential short squeezes. Traders are actively debating the company's valuation, low-float structure, and the risks of potential future dilutions as the stock remains a focal point for momentum scalp strategies.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing extreme volatility and heavy retail interest driven by a low-float structure and speculative momentum rather than fundamental news. The community is actively debating the stock's potential for a massive short squeeze against its history of sharp pullbacks, with many traders cautioning that it exhibits the classic behavioral patterns of a pump-and-dump scheme.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu.</li><li>Vepannu, developed by Arvinas and Pfizer, received FDA approval earlier this month.</li><li>Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities.</li></ul>Shares of Rigel Pharmaceuticals, Inc (RIGL) surged more than 15% on Tuesday after investors welcomed a potential growth opportunity tied to the company’s newly signed global licensing deal with Arvinas (ARVS) and Pfizer (PFE) for a breast cancer treatment.According to Koyfin data, short interest in <a href="https://stocktwits.com/symbol/RIGL">RIGL</a> climbed to 22.3% of the float as of May 12, up sharply from 15.5% at the beginning of the year, marking its highest level ever. The company has roughly 18.5 million outstanding shares.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://app.koyfin.com/charts/g/eq-stzcug"><img src="https://news.stocktwits-cdn.com/Rigel_jpg_90c3024bd7.webp" alt="Rigel.jpg"></a>Source: Koyfin<h2 class="st-heading-2">Veppanu To Drive RIGL’s Revenue Growth</h2>Under the agreement, Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu. The drug is the only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC) therapy, a new class of medicines designed to target and break down disease-causing proteins.Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities. The companies could also receive up to $320 million in future milestone payments.Rigel said Veppanu will become its fourth commercial product and a key driver of future revenue growth as it expands its cancer treatment portfolio.“Veppanu is expected to contribute strong revenue growth in our expanding commercial portfolio, and we believe it has the potential to become a meaningful driver of long-term growth for Rigel,” said Raul Rodriguez, Rigel’s president and CEO.<h2 class="st-heading-2">Vepannu’s Phase 3 Data Shows 43% Fall In Disease Progression Risk</h2>The drug, developed by Arvinas and Pfizer, received FDA<a href="https://stocktwits.com/news-articles/markets/equity/arvn-stock-gains-fda-approval-breast-cancer-drug-pfizer/cZQVgmpReen">&nbsp;approval</a> earlier this month. The regulatory clearance was supported by a Phase 3 study showing that Veppanu reduced the risk of disease progression or death by 43% compared with the comparator cancer drug, Fulvestrant. Patients treated with Veppanu had a median progression-free survival of five months, compared with 2.1 months for Fulvestrant.Following the FDA approval, Arvinas announced plans to partner with a third party to support the drug’s commercial rollout. Veppanu received Fast Track designation from the FDA in 2024, followed by the agency’s acceptance of its New Drug Application (NDA) for review last August.<h2 class="st-heading-2">RIGL Bulls Eyes $50</h2>Retail sentiment for RIGL shares on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to climb to $50, a 40% upside from current levels, stating Rigel is no longer “just a company managing a future patent cliff” but is a “growing commercial oncology company.”<stembedurl>https://stocktwits.com/ExtraRun123/message/653075404</stembedurl>Another user called the deal a “potential game-changer.”<stembedurl>https://stocktwits.com/Ou8mycookie/message/653059707</stembedurl>The stock has gained more than 14% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-has-gained-nearly-16-in-a-month-but-wall-street-sees-further-upside/cZXXhJWReiX">NVDA Stock Has Gained Nearly 16% In A Month – But Wall Street Sees Further Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. MRAM and HPAI stocks surged in overnight trading (Image source: Getty Images)

RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

Equity

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Rigel Enters Exclusive...

Rigel Pharmaceuticals Q1 Earnings Call Highlights

Rigel Pharmaceuticals (NASDAQ:RIGL) reported first-quarter 2026 results that management said reflected continued year-over-year growth across its three-product portfolio, while reiterating full-year guidance and highlighting upcoming data milestones for its R289 program in lower-risk myelodysplastic...

Rigel Pharmaceuticals Inc. Profit Falls In Q1

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) announced earnings for first quarter that Dropped, from last year...

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.80 by ($0.36). The firm had revenue of $58.82 million during the quarter, compared to analysts...

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports First Quarter 2026 Financial Results

Rigel Reports First Quarter 2026 Financial Results Rigel Reports First Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., May 5, 2026 First quarter 2026 total revenues of $58.8...

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) to Release Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Bill passes both chambers

Senate yes, House stalls

Banking advances, full Senate punts

Nothing meaningful

Senate Banking holds the CLARITY Act hearing May 14. What gets done in 2026?

Stocktwits

Stocktwits Polls

Investors are buzzing about the potential for VEPPANU to drive $1B in future revenue after a major new licensing deal.

Speculation is mounting that high short interest could fuel a massive move upward as shorts struggle to exit positions.

Some traders are questioning the lack of price momentum despite major news, warning of potential traps or exhaustion for long positions.

Current Price	$28.09
Prev Close	$26.20
Open	$28.09
Dividend Yield	0.00%
50-Day Moving Average	$28.64
Beta	1.30
Avg. Volume	349,490.13
PE Ratio	1.40

52-Week High	$52.24
52-Week Low	$17.65
Market Capitalization	$484.75M
EPS (Annual)	$19.48
Price to Book	1.21
Revenue Per Employee	$1.69M

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIGL News

RIGLRigel Pharmaceuticals